

Commercial Paper Programs

February 1, 2021

Jerry Marlatt

Partner, Mayer Brown

+1 212 506 2539

jmarlatt@mayerbrown.com

Stewart Cutler

Director, Barclays

stewart.cutler@barclays.com

What is Commercial Paper?

- Commercial paper is a term that tends to be used to refer to corporate short-term debt securities. Maturities are typically less than 12 months.
- Classically, commercial paper meant debt securities issued under Section 3(a)(3) of the Securities Act.
- There has also developed a market in short-term corporate debt issued under Section 4(a)(2) of the Securities Act.
- There are differences between the two types of commercial paper in terms of investor base, use of proceeds and securities law requirements for issuance.

Historical Roots

- The legislative history of the Securities Act provides an explanation of the genesis of Section 3(a)(3).
- Commercial paper was issued by merchants and manufacturers for short-term financing of operations and was sold primarily to banks through commercial paper dealers.
- There was a concern that if short-term paper that arises out of or finances current transactions and rarely bought by private investors were required to be registered, it would radically interfere with commercial banking transactions.
- The original Federal Reserve Act included commercial paper as an instrument rediscountable by Federal Reserve banks.
- In 1933, the Federal Reserve requested an exemption for commercial paper and provided the language that became Section 3(a)(3).

Section 3(a)(3) Requirements

- Section 3(a)(3) provides an exemption from the registration requirements of the Securities Act for:
 - Any note, draft, bill of exchange, or banker’s acceptance which arises out of a current transaction or the proceeds of which have been or are to be used for current transactions, and which has a maturity at the time of issuance of not exceeding nine months, exclusive of days of grace, or any renewal thereof the maturity of which is likewise limited;
- In 1961, the SEC stated in Rel. 33-4412:
 - The legislative history of the Securities Act makes clear that Section 3(a)(3) applies only to prime quality negotiable commercial paper of a type not ordinarily purchased by the general public, that is, paper issued to facilitate well-recognized types of current operational business requirements and of a type discountable by Federal Reserve banks.
 - [T]he staff of the Commission has interpreted Section 3(a)(3) to exclude as not satisfying the nine-month maturity standard, obligations payable on demand or having provisions for automatic “roll-over.”

Section 3(a)(3) Requirements *(cont'd)*

- The SEC imposed six separate characteristics as necessary for qualifying for Section 3(a)(3):
 1. Negotiable
 2. Prime quality
 3. Eligible for discount at Federal Reserve banks
 4. Not ordinarily purchased by the general public
 5. Used to facilitate “current transactions”
 6. Maturity of nine months or less with no automatic roll-over

“Current Transactions”

- Through a long series of no-action letters, the staff has defined current transaction for a variety of businesses.
- Traditionally, it was necessary to trace the use of proceeds to identifiable current transactions.
- Today, following a 1986 staff response, it is only necessary to demonstrate that current transactions on the balance sheet exceed the amount of commercial paper outstanding at any time.
- Inventories and accounts receivable have long been accepted as current transactions. Also operating expenses, such as salaries, short-term lending, federal, state and local taxes, and various types of bank loans with maturities not exceeding five years, have been accepted.
- However, acquisition financing is **NOT** considered a current transaction.

Section 3(a)(3) as Public Offering

- Section 3(a)(3) provides an exemption from the requirement in Section 5 of the Securities Act to register any offer or sale of securities with the SEC.
- 3(a)(3) commercial paper is not a privately placed security
 - This is important, for example, in connection with 1940 Act exemptions under Sections 3(c)(1) and 3(c)(7), which may not be used if the issuer is making a public offering.
- To meet the “not ordinarily purchased by the general public” standard, commercial paper is normally issued in minimum denominations of \$100,000, although occasionally you will see \$25,000 minimum denominations.
- 3(a)(3) commercial paper is usually rated “A-1” to satisfy the prime quality standard.

Continuous Issuance

- Commercial paper is issued in continuously offered programs.
- Typical maturities are in the range of 7 to 21 days
 - See FRB H.15 releases and the Commercial Paper releases for maturity distributions and other statistics.
 - *Volume statistics are available at:* <http://www.federalreserve.gov/releases/CP/volumestats.htm>
- Proceeds of commercial paper are often used to pay off maturing commercial paper.
- In the days before shelf registration, it would have been impossible to issue this frequently if registration were required.
- And even today, the registration costs would be prohibitive considering the high frequency of issuance.

Book-entry Considerations

- Since 1990, virtually all commercial paper is issued in book-entry form through DTC or other clearing entities.
- The issuing and paying agent (or depository bank) holds a master note for the benefit of DTC and records on its records daily issuance and redemptions of commercial paper.
- There is generally no involvement of counsel in daily issuances.
- Companies issue commercial paper by direct calls to a dealer's commercial paper desk.
- Upon agreement on terms, dealers will buy the entire daily issuance and resell to investors.

Private Commercial Paper

- Nowadays, commercial paper may also be issued under Section 4(a)(2) as a private placement of securities.
- Historically, the 3(a)(3) market was larger and deeper than the 4(a)(2) market because privately placed securities are restricted securities.
- Today, the two markets provide about the same liquidity.
- The advantage of Section 4(a)(2) is that the section does not have any maturity limitations, so longer dated paper can be issued, and proceeds do not have to be used for current transactions.
- Most privately placed commercial paper is issued in Rule 144A programs, although some programs still issue to institutional accredited investors.

4(a)(2) Requirements

- Historically, private placements were conducted under old Section 4(2) with resales to a limited number of investors under the so-called Section 4(1^{1/2}) exemption. This sharply limited the size of the market.
- Today, between Regulation D and Rule 144A, the private placement market is approaching the public securities market in size.
- Until the recent enactment of the JOBS Act, the prohibition on general solicitations in Rule 502(c) applied to commercial paper issued under Section 4(a)(2).
 - Occasionally, issuers would trip over this limitation and have to stay out of the market for 30 to 60 days.

JOB Act Changes to 4(a)(2) Offers

- Title II of the Jumpstart Our Business Startups (JOBS) Act of 2012 directed the SEC to eliminate the ban on general solicitation and general advertising for certain offerings under Rule 506 of Regulation D and under Rule 144A.
- Under the SEC rulemaking, new paragraph (c) was added to Rule 506 to permit general solicitations under certain circumstances.
- Incidentally, this rulemaking now permits general solicitation in an offering even though the issuer is relying on Section 3(c)(1) or 3(c)(7) of the 1940 Act, which prohibits a public offering.
- Thus, a Rule 144A program no longer risks being out of the market for 30 to 60 days as a result of an inadvertent publicity problem.

JOB Act Changes to 4(a)(2) Offers *(cont'd)*

- However, in order to use general solicitation under Rule 506(c), the issuer and offering participants must not be “bad actors.”
 - An offering is disqualified from relying on Rule 506(c) if a “covered person” has a relevant criminal conviction, regulatory or court order or other disqualifying event.
 - “**Covered persons**” include: (1) the issuer, including its predecessors and affiliated issuers; (2) directors, general partners, and managing members of the issuer; (3) executive officers of the issuer, and other officers of the issuers that participate in the offering; (4) 20% beneficial owners of the issuer, calculated on the basis of total voting power; (5) promoters connected to the issuer; (6) for pooled investment fund issuers, the fund’s investment manager and its principals; **and** (7) persons compensated for soliciting investors, including their directors, general partners and managing members.
- Certifications as to bad actor status are time consuming to obtain and this is not practical for commercial paper which can be issued daily.
- As a result, issuers and dealers do not use general solicitation and instead rely just on Section 4(a)(2) rather than Rule 506(c)

Amended “accredited investor”

- In August (Rel. 33-10824), the SEC adopted amendments to the definition of “accredited investor” and the definition of “QIB”
 - Added any entity not listed in (a)(1), (2), (3), (7), or (8) with at least \$5M of investments
 - That addition clarifies that municipalities and other government entities qualify
 - Also added “family office” and “family client”
- QIB definition amended to add any institutional accredited investor not listed in 144A(a)(1)(i)(A) through (I) or (a)(1)(ii) through (vi)
 - And it may be formed for the purpose of acquiring the securities offered

Use of Proceeds of 4(a)(2) Paper

- One of the advantages of 4(a)(2) commercial paper is that there is no requirement to use the proceeds for current transactions.
- 4(a)(2) commercial paper programs are often used to finance acquisitions until term financing can be arranged.
- Proceeds can be used for any legitimate purpose consistent with the board resolutions for the program.

Disadvantages of 4(a)(2) Paper

- 4(a)(2) commercial paper is still a “restricted security.”
- Some investors have limits on the amount that they can invest in restricted securities.
- This might have some impact in the secondary market, but generally the secondary market is a dealer market, i.e., most sales in the secondary market are back to dealers who may hold or may resell the paper to other customers.

Conversion of 3(a)(3) to 4(a)(2)

- It is not uncommon for issuers to convert 3(a)(3) commercial paper programs to 4(a)(2) programs.
- Historically, there were transition issues in moving from a public offering program to a privately placed program to avoid integration of the private program with the public program while losing the 3(a)(3) exemption.
- This was addressed by covenants to use the proceeds for current transactions, but to make sales only to QIBs, for a six month period.
- With the changes brought about by the JOBS Act, this overlap should no longer be necessary to deal with the general solicitation issues created by the 3(a)(3) programs.

Side-by-side Programs

- Some issuers still operate side-by-side 3(a)(3) and 4(a)(2) programs.
- Historically, there had to be careful segregation of proceeds and use of proceeds, and perhaps different maturities to deal with the integration issue.
- Today, after the JOBS Act, the integration concern from general solicitation is removed but also perhaps there is no longer a reason to operate two programs.

Financial Institution Issuance

- Financial institutions account for about 60% of commercial paper issuance.
- 2/3 of that is from foreign financial institutions
- Domestic banks rely on Section 3(a)(2) for their exemption from the registration requirements
 - If OCC registered then must comply of Part 16 of the OCC's rules
- Branches and agencies of foreign banks also rely on Section 3(a)(2)
 - 1986 SEC Release 33-6661 is an interpretive release
 - If OCC registered then must also comply with Part 16 of OCC rules
- Foreign banks may issue directly under either Section 3(a)(3) or Section 4(a)(2)
 - Some banks have a U.S. branch program and a home office program

Asset-Backed Commercial Paper

- Starting in the 1980s, asset-backed commercial paper (ABCP) programs become common.
- Under accounting rules at the time, the sponsor of the program could operate the program off-balance sheet, so no capital was required to be held against the assets.
- Numerous ABCP programs foundered during the financial crisis and today they are much less common; ABCP volumes have declined from a high of about \$1.2 trillion to less than \$300 billion today.
- Revised accounting rules and other regulatory developments have made it increasingly difficult to maintain these programs off-balance sheet, so much of the reason for their separate existence is gone.
- They are still used, however, for trade receivables financing and other short-term, maturity-matched lending situations.

1940 Act Considerations

- With ABCP, because the issuer is an SPV and not an operating company, it is necessary to consider what exemption from the 1940 Act may be available.
- Many ABCP programs previously relied on Sections 3(c)(1) or 3(c)(7) for an exemption.
- For bank sponsors, the Volcker Rule will now require a careful examination of other possible exemptions under the 1940 Act or exemptions under the Volcker Rule from the definition of “covered fund.”
- Section 3(c)(5) of the 1940 Act or Rule 3a-7 under the 1940 Act are possibilities and also compliance with the definition of “qualifying asset-backed commercial paper conduit” under the Volcker Rule.
- If swaps are used in the program, attention must also be paid to the Commodity Exchange Act and initial and variation margin requirements.

Disclosure Considerations

- Disclosure practices for commercial paper developed from the historical antecedent of Section 3(a)(3), where commercial paper was used for commercial banking transactions.
- Section 3(a)(3) itself does not impose any disclosure requirements.
- Disclosure documents for commercial paper have traditionally been very brief, providing little more than identification of the issuer. Accordingly the offering documents may be little more than a term sheet.
- 4(a)(2) commercial paper adopted the same disclosure approach.
- As a consequence, 10b-5 letters from counsel are not utilized in the commercial paper market.

Issuing Documents

- Issuing Agreement
 - Issuing and Paying Agency Agreement
 - Depositary Agreement
- Agreement with distributing dealer
 - Commercial Paper Dealer Agreement
 - Private Placement Agreement
- Disclosure Document
 - Offering Circular
 - Private Placement Memorandum
- Liquidity Agreement

Practical Considerations

- Maturity limits on 4(a)(2) commercial paper:
 - Seldom sold with maturities longer than 390 days, a limit determined by money market fund considerations, as money market funds have traditionally been very active purchasers of commercial paper;
 - MTN and senior note programs are usually established for issuance of maturities of one year or more;
 - Generally, investment banks have separate desks for commercial paper and MTN and senior note programs;
 - MTN and senior note programs have more traditional prospectus disclosure; at longer maturities, the rationale for brief disclosure documents is not supported.

Securities Law Liability

- No liability under Section 11 of the Securities Act for issuers with respect to 3(a)(3) or 4(a)(2) programs.
- After *Gustafson v. Alloyd*, there is no liability under Section 12(a)(2) of the Securities Act for privately placed commercial paper.
- Section 17 of the Securities Act will support SEC actions, but not investor actions.
- Sections 12(a)(2) and 17 of the Securities Act apply to 3(a)(2) commercial paper, notwithstanding the exemption from registration provided by Section 3(a)(3).

Securities Law Liability *(cont'd)*

- For investors, Rule 10b-5 under the Securities Exchange Act provides principal remedy against both dealers and issuers.
 - Consider the exclusion from the definition of a “security” in Section 3(a)(10) of the Securities Exchange Act for “any note which has a maturity at the time of issuance of not exceeding nine months,” which appears to exclude 3(a)(3) commercial paper. However, notes which fail the ‘prime quality’ standard have been held to fall outside this exclusion.
- After the SEC’s enforcement proceeding settlement against Goldman Sachs in the 1974 arising out of the Penn Central bankruptcy and commercial paper default, many dealers have assumed that they will be unable to avoid liability for any defaulted commercial paper.
- The SEC stated that Goldman had failed to conduct a reasonable investigation of Penn Central and had implicitly represented to its customers that the issuer was creditworthy.

Due Diligence Defense

- Classic due diligence inquiry not possible due to issuance mechanics
- No 10b-5 opinions are given
- No accountant's comfort letters are received
- There is no questioning of management prior to each issuance
- Thus, there can be no "reasonable investigation"
- Some dealers established credit departments to monitor their issuers continuously
- Generally, dealers act defensively and rating downgrades or headline events can lead to dealers and investors refusing to roll over an issuer's commercial paper, forcing the issuer to rely on bank lines of credit

Issuance Volumes

Source (as of January 27, 2021): www.federalreserve.gov/releases/cp

Period	Total	Nonfinancial			Financial			Asset-backed	Other
		Total	Domestic	Foreign	Total	Domestic	Foreign		
Monthly-end levels									
2020-Aug.	997.0	209.9	142.2	67.7	544.2	185.3	358.9	242.9	.0
Sept.	956.9	183.4	122.2	61.2	532.8	165.3	367.5	240.7	.0
Oct.	966.1	198.4	133.1	65.4	528.2	173.8	354.5	239.4	.0
Nov.	982.7	189.9	127.0	62.9	549.5	185.8	362.2	243.2	.1
Dec.	986.9	180.9	132.1	48.8	549.6	165.1	381.6	256.3	.1
Weekly (Wednesday) levels									
Dec. 23	1,032.4	188.3	134.2	54.1	588.6	198.9	386.9	255.4	.1
Dec. 30	1,010.8	183.7	133.4	50.3	570.0	186.2	381.0	257.1	.1
Jan. 6	1,039.3	187.8	132.8	55.0	594.1	192.3	398.6	257.3	.1
Jan. 13	1,062.7	192.4	136.1	56.2	613.8	201.9	408.7	256.4	.1
Jan. 20	1,067.6	198.8	139.9	58.9	613.6	205.8	404.1	255.1	.1




US and Euro Commercial Paper Market

February 1, 2021

US Commercial Paper Market


USCP Monthly Outstandings (by Type)



Source: Federal Reserve

Euro Commercial Paper Market

ECP Outstandings by Sector



Source: CMD

Disclaimer

This document has been prepared by Barclays Capital Inc. ("Barclays") for information purposes only and for the sole and exclusive use of recipient (the "Recipient") in connection with the matter or possible transaction to which this document relates. The final terms and conditions of the transaction will be set out in full in the applicable offering document(s) or binding transaction document(s). This document is incomplete without reference to, and should be assessed solely in conjunction with, the oral briefing provided by Barclays.

This document is strictly confidential and remains the property of Barclays. The Recipient agrees that it shall only use this document for the purpose of evaluating and considering the matter or possible transaction to which this document relates. This document may not be distributed, published, reproduced, or disclosed, in whole or in part, to any other person, nor relied upon by the Recipient or any other person, nor used for any other purpose at any time, in each case without the prior written consent of Barclays.

Members of Barclays and its subsidiaries, affiliates, respective officers, directors, employees, agents, advisors and other representatives (Barclays together with such persons being the "Barclays Group") are involved in a wide range of commercial banking, investment banking and other activities out of which conflicting interests or duties may arise. In the ordinary course of its business, Barclays Group may provide services to any other entity or person whether or not a member of the same group as the Recipient (a "Third Party"), engage in any transaction (whether on its own account, on behalf of any Third Party or otherwise, and including any transaction or matter contemplated by this document), notwithstanding that such services, transactions or actions may be adverse to the Recipient or any member of the Recipient's group, and Barclays Group may retain for its own benefit any related remuneration or profit. Barclays Group may also, from time to time, effect transactions for its own account or the account of its clients and hold long or short positions in debt, equity or other securities of the companies referred to herein or in other financial products and instruments. Unless otherwise expressly agreed or provided for in other applicable Barclays disclosures governing such transactions or required by law or regulation, Barclays conducts these activities as principal and executes its principal transactions as an arm's length counterparty. Barclays does not act as a fiduciary in relation to these transactions. Barclays Group operates in accordance with a conflicts of interest policy that identifies conflicts of interest. Barclays Group faces in the ordinary course of its business, and establishes organizational and procedural measures to manage those conflicts where it is reasonably able to do so. Neither Barclays nor any other part of Barclays Group shall have any duty to disclose to the Recipient or utilize for the Recipient's benefit any non-public information acquired in the course of providing services to any other person, engaging in any transaction (on its own account or otherwise) or otherwise carrying on its business.

The Barclays Group's research analysts and research departments are independent from the Barclays Group's banking business ("Banking") and are subject to certain regulations and internal policies. The Barclays Group's research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to any company referred to herein, the transactions contemplated herein or any person involved therein or related thereto that differ from or are inconsistent with the views or advice communicated by Banking.

Furthermore, any preliminary valuation summary presented herein represents the views of Banking. In the course of vetting potential transactions and pursuant to Barclays' internal preliminary valuation, diligence and compliance procedures, Banking may obtain the independent views of the Barclays Group's research department regarding the company and merits of a proposed transaction. However, the Barclays Group's research department is independent and, in accordance with U.S. rules, Banking is not permitted to make any representation regarding the views of the research analyst who has been, or may be, assigned by research management to independently evaluate a company and any proposed transaction. Accordingly, you should not infer that any preliminary valuation summary presented by Banking reflects the views of the Barclays Group's research department and nothing herein or otherwise should be construed as a promise or offer of favorable coverage or an indication of a specific rating or price target that may be assigned in the future by any Barclays Group research analyst.

Neither Barclays nor any of its subsidiaries or affiliates shall be obliged by having made this document available to you to provide any financial advisory services (whether in relation to the matter or possible transaction to which this document relates or otherwise) or to sell, acquire, place or underwrite any securities or to lend moneys or to provide any other commitment, facility, product, risk management solution or service, nor does Barclays represent by providing this document to the Recipient that it will be possible for Barclays to provide, arrange or undertake any of the aforementioned services, activities, products or solutions. Any commitment by Barclays to provide, arrange or undertake any of the aforementioned services, activities, products or solutions would be subject to Barclays signing appropriate documentation, obtaining all necessary internal approvals and completing due diligence, in each case in a manner satisfactory to Barclays.

This document was prepared on the basis of information and data obtained from publicly available sources and, where applicable, from the Recipient and/or any other entity that may be involved in any transaction or matter contemplated by this document (and/or any of the Recipient's or the aforementioned entities' affiliates), in each case prior to or on the date hereof. The information in this document has not been independently verified by Barclays. Barclays has relied on any information provided by the Recipient or from third party or public sources as complete, true, fair, accurate and not misleading. With respect to any financial or operating forecasts and analyses provided to it, Barclays has assumed that they are achievable and have been reasonably and properly prepared on bases reflecting the best currently available information, estimates and judgments as to the future financial performance of the entity(ies) to which they relate and that such forecasts or analyses would be realized in the amounts and time periods contemplated thereby. Barclays does not make any warranty or representation, express or implied, as to the accuracy, completeness or reasonableness of the information (including projections and assumptions) contained in this document whether obtained from or based upon third party or public sources or otherwise.

This document is given as of the date hereof, may not be final, is based on information available to Barclays as of the date hereof, is subject to any assumptions set out therein and is subject to change without notice. Accordingly, this document may be based on (a) data and information that may no longer be current and (b) estimates that may involve highly subjective assessments. It should be understood that subsequent developments may affect this document and Barclays Group (as defined below) does not undertake any obligation to provide any additional information or to update any of the information or the conclusions contained herein or to correct any inaccuracies which may become apparent. Any data or information regarding, or based on, past performance is no indication of future performance.

The Recipient is responsible for making its own independent investigation and appraisal of the risks, benefits, appropriateness and suitability of any transaction or matter contemplated by this document. Barclays is not making any recommendation (personal or otherwise) or giving any investment advice. The decision to proceed with any transaction or action contemplated by this document must be made by the Recipient in light of its own commercial assessments, and Barclays will not be responsible for such assessments. Barclays is not responsible for providing or arranging for the provision of any general financial, strategic or specialist advice, including legal, regulatory, accounting, model auditing or taxation advice or services or any other services in relation to the transaction and/or any related securities described herein.

Barclays Group does not accept any liability whatsoever for any direct, indirect or consequential losses (in contract, tort or otherwise) arising from the use of this document or its contents or any reliance on the information contained herein. Barclays Group is not responsible for any specialist advice, including legal, regulatory, accounting, model accounting, tax, actuarial or other advice.

This document shall not constitute an underwriting commitment, an offer of financing, an offer to sell, or the solicitation of an offer to buy any securities described herein, which shall be subject to Barclays' internal approvals. No transaction or service related thereto is contemplated without Barclays' subsequent formal agreement.

NO ACTION HAS BEEN MADE OR WILL BE TAKEN THAT WOULD PERMIT A PUBLIC OFFERING OF THE SECURITIES DESCRIBED HEREIN IN ANY JURISDICTION IN WHICH ACTION FOR THAT PURPOSE IS REQUIRED. NO OFFERS, SALES, REALES OR DELIVERY OF THE SECURITIES DESCRIBED HEREIN OR DISTRIBUTION OF ANY OFFERING MATERIAL RELATING TO SUCH SECURITIES MAY BE MADE IN OR FROM ANY JURISDICTION EXCEPT IN CIRCUMSTANCES WHICH WILL RESULT IN COMPLIANCE WITH ANY APPLICABLE LAWS AND REGULATIONS AND WHICH WILL NOT IMPOSE ANY OBLIGATION ON BARCLAYS OR ANY OF ITS AFFILIATES.

THIS DOCUMENT DOES NOT DISCLOSE ALL THE RISKS AND OTHER SIGNIFICANT ISSUES RELATED TO AN INVESTMENT IN THE SECURITIES DESCRIBED HEREIN. PRIOR TO TRANSACTING, POTENTIAL INVESTORS SHOULD ENSURE THAT THEY FULLY UNDERSTAND THE TERMS OF THE RELEVANT SECURITIES AND ANY APPLICABLE RISKS.

THE INFORMATION CONTAINED HEREIN IS NOT INTENDED TO BE DISTRIBUTED TO ANY PROSPECTIVE OR ACTUAL INVESTORS AND, ACCORDINGLY, MAY NOT BE SHOWN OR GIVEN TO ANY PERSON OTHER THAN THE RECIPIENT, AND IS NOT TO BE FORWARDED TO ANY OTHER PERSON (INCLUDING ANY RETAIL INVESTOR OR CUSTOMER), COPIED OR OTHERWISE REPRODUCED OR DISTRIBUTED TO ANY SUCH PERSON IN ANY MANNER WHATSOEVER. FAILURE TO COMPLY WITH THIS DIRECTIVE CAN RESULT IN A VIOLATION OF THE SECURITIES ACT OF 1933, AS AMENDED.

In 2017, the United Kingdom's Financial Conduct Authority announced that it will no longer persuade or compel banks to submit rates for the calculation of the London interbank offered rate ("LIBOR") benchmark after 2021. This announcement indicates that the continuation of LIBOR (including US\$ LIBOR) on the current basis cannot and will not be guaranteed after 2021. EURIBOR has been reformed in 2019 and is expected to continue to be published after end-2021. Central banks have identified replacement rates, but the timing of and mechanisms for implementation have not yet been confirmed. Accordingly, it is not currently possible to determine whether, or to what extent, any such changes would affect the recipient of this document. Structuring an instrument that relies on a calculation of an IBOR to determine its value or return of interest or principal includes certain risks that the recipient should be aware of, including, but not limited to: (i) risks relating to the value, return or performance of the instrument; (ii) risks relating to any changes required to documentation in the future; (iii) litigation and conduct risk relating to the recipient's ability to meet its obligations under the instrument and/or any related economic losses suffered by holders as a result of LIBOR (including US\$ LIBOR), EURIBOR or other IBOR or benchmark discontinuation; (iv) regulatory risk relating to compliance with future legislative or regulatory requirements and (v) operational risks relating to the cost and ability to deliver against any changes in the transitional period. Barclays encourages the recipient to seek independent legal advice if it is concerned about the risks its business faces in light of benchmark reform. More information is available in Barclays FAQs which are available at <https://home.barclays/libor-transition/>

Barclays Capital Inc. is the United States investment bank of Barclays Bank PLC. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority (Financial Services Register No. 122702). Registered in England. Registered No. 1026167. Registered office: 1 Churchill Place, London E14 5HP. Copyright Barclays Bank PLC, 2020 (all rights reserved).



[Americas](#) | [Asia](#) | [Europe](#) | [Middle East](#)

mayerbrown.com

Mayer Brown is a global services provider comprising associated legal practices that are separate entities, including Mayer Brown LLP (Illinois, USA), Mayer Brown International LLP (England), Mayer Brown (a Hong Kong partnership) and Tauil & Chequer Advogados (a Brazilian law partnership) (collectively the "Mayer Brown Practices") and non-legal service providers, which provide consultancy services (the "Mayer Brown Consultancies"). The Mayer Brown Practices and Mayer Brown Consultancies are established in various jurisdictions and may be a legal person or a partnership. Details of the individual Mayer Brown Practices and Mayer Brown Consultancies can be found in the Legal Notices section of our website. "Mayer Brown" and the Mayer Brown logo are the trademarks of Mayer Brown. © Mayer Brown. All rights reserved.